This may due to inadequate sample size, variations in population demographics, tumor heterogeneity, and discrepancies in assessment methods utilized across various studies, including antibody clones, evaluation criteria, and cut-offs applied for defining HER2 positivity. This evidence concerns the gene ERBB2 and neoplasm.